Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Teresa Starzyńska
Based on 16 articles published since 2008
||||

Between 2008 and 2019, Teresa Starzyńska wrote the following 16 articles about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Guideline Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours). 2017

Kos-Kudła, Beata / Blicharz-Dorniak, Jolanta / Strzelczyk, Janusz / Bałdys-Waligórska, Agata / Bednarczuk, Tomasz / Bolanowski, Marek / Boratyn-Nowicka, Agnieszka / Borowska, Małgorzata / Cichocki, Andrzej / Ćwikła, Jarosław B / Falconi, Massimo / Foltyn, Wanda / Handkiewicz-Junak, Daria / Hubalewska-Dydejczyk, Alicja / Jarząb, Barbara / Junik, Roman / Kajdaniuk, Dariusz / Kamiński, Grzegorz / Kolasińska-Ćwikła, Agnieszka / Kowalska, Aldona / Król, Robert / Królicki, Leszek / Krzakowski, Maciej / Kunikowska, Jolanta / Kuśnierz, Katarzyna / Lampe, Paweł / Lange, Dariusz / Lewczuk-Myślicka, Anna / Lewiński, Andrzej / Lipiński, Michał / Londzin-Olesik, Magdalena / Marek, Bogdan / Nasierowska-Guttmejer, Anna / Nawrocki, Sergiusz / Nowakowska-Duława, Ewa / Pilch-Kowalczyk, Joanna / Rosiek, Violetta / Ruchała, Marek / Siemińska, Lucyna / Sowa-Staszczak, Anna / Starzyńska, Teresa / Steinhof-Radwańska, Katarzyna / Sworczak, Krzysztof / Syrenicz, Anhelli / Szawłowski, Andrzej / Szczepkowski, Marek / Wachuła, Ewa / Zajęcki, Wojciech / Zemczak, Anna / Zgliczyński, Wojciech / Zieniewicz, Krzysztof. ·Klinika Endokrynologii i Nowotworów Neuroendokrynnych, Katedra Patofizjologii i Endokrynologii, Śląski Uniwersytet Medyczny. endoklin@sum.edu.pl. ·Endokrynol Pol · Pubmed #28597909.

ABSTRACT: Progress in the diagnostics and therapy of gastro-entero-pancreatic (GEP) neuroendocrine neoplasms (NEN), the published results of new randomised clinical trials, and the new guidelines issued by the European Neuroendocrine Tumour Society (ENETS) have led the Polish Network of Neuroendocrine Tumours to update the 2013 guidelines regarding management of these neoplasms. We present the general recommendations for the management of NENs, developed by experts during the Third Round Table Conference - Diagnostics and therapy of gastro-entero-pancreatic neuroendocrine neoplasms: Polish recommendations in view of current European recommenda-tions, which took place in December 2016 in Żelechów near Warsaw. Drawing from the extensive experience of centres dealing with this type of neoplasms, we hope that we have managed to develop the optimal management system, applying the most recent achievements in the field of medicine, for these patients, and that it can be implemented effectively in Poland. These management guidelines have been arranged in the following order: gastric and duodenal NENs (including gastrinoma); pancreatic NENs; NENs of the small intestine and appendix, and colorectal NENs.

2 Guideline Pancreatic neuroendocrine neoplasms - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours). 2017

Kos-Kudła, Beata / Rosiek, Violetta / Borowska, Małgorzata / Bałdys-Waligórska, Agata / Bednarczuk, Tomasz / Blicharz-Dorniak, Jolanta / Bolanowski, Marek / Boratyn-Nowicka, Agnieszka / Cichocki, Andrzej / Ćwikła, Jarosław B / Falconi, Massimo / Foltyn, Wanda / Handkiewicz-Junak, Foltyn / Hubalewska-Dydejczyk, Alicja / Jarząb, Barbara / Jarząb, Michał / Junik, Roman / Kajdaniuk, Dariusz / Kamiński, Grzegorz / Kolasińska-Ćwikła, Agnieszka / Kowalska, Aldona / Król, Robert / Królicki, Leszek / Kunikowska, Jolanta / Kuśnierz, Katarzyna / Lampe, Paweł / Lange, Dariusz / Lewczuk-Myślicka, Anna / Lewiński, Andrzej / Lipiński, Michał / Londzin-Olesik, Magdalena / Marek, Bogdan / Nasierowska-Guttmejer, Anna / Nowakowska-Duława, Ewa / Pilch-Kowalczyk, Joanna / Ruchała, Marek / Siemińska, Lucyna / Sowa-Staszczak, Anna / Starzyńska, Teresa / Steinhof-Radwańska, Katarzyna / Strzelczyk, Janusz / Sworczak, Krzysztof / Syrenicz, Anhelli / Szawłowski, Andrzej / Szczepkowski, Marek / Wachuła, Ewa / Zajęcki, Wojciech / Zemczak, Anna / Zgliczyński, Wojciech. ·vml@wp.pl. ·Endokrynol Pol · Pubmed #28540973.

ABSTRACT: This article presents updated diagnostic and therapeutic guidelines for the management of pancreatic neuroendocrine tumours (PNEN), proposed by the Polish Network of Neuroendocrine Tumours. The guidelines contain new data received in the years 2013-2016, which confirm previous recommendations, and have led to modification of previous guidelines or have resulted in the formulation of new guidelines. Biochemical and imaging (anatomical and functional) tests are of great importance in diagnostics, as well as histopathological diagnosis to determine the management of PNEN patients, but they must be confirmed by an immunohistochemical examination. PNEN therapy requires collaboration among the members a multidisciplinary team of specialists experienced in the management of these neoplasms. Surgery is the basic form of treatment in many cases. Further therapy requires a multidirectional procedure; therefore, the rules of biotherapy, peptide receptor radionuclide therapy, molecular targeted therapy, and chemotherapy are discussed.

3 Guideline Gastroduodenal neuroendocrine neoplasms, including gastrinoma - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours). 2017

Lipiński, Michał / Rydzewska, Grażyna / Foltyn, Wanda / Andrysiak-Mamos, Elżbieta / Bałdys-Waligórska, Agata / Bednarczuk, Tomasz / Blicharz-Dorniak, Jolanta / Bolanowski, Marek / Boratyn-Nowicka, Agnieszka / Borowska, Małgorzata / Cichocki, Andrzej / Ćwikła, Jarosław B / Falconi, Massimo / Handkiewicz-Junak, Daria / Hubalewska-Dydejczyk, Alicja / Jarząb, Barbara / Junik, Roman / Kajdaniuk, Dariusz / Kamiński, Grzegorz / Kolasińska-Ćwikła, Agnieszka / Kowalska, Aldona / Król, Robert / Królicki, Leszek / Kunikowska, Jolanta / Kuśnierz, Katarzyna / Lampe, Paweł / Lange, Dariusz / Lewczuk-Myślicka, Anna / Lewiński, Andrzej / Londzin-Olesik, Magdalena / Marek, Bogdan / Nasierowska-Guttmejer, Anna / Nowakowska-Duława, Ewa / Pilch-Kowalczyk, Joanna / Poczkaj, Karolina / Rosiek, Violetta / Ruchała, Marek / Siemińska, Lucyna / Sowa-Staszczak, Anna / Starzyńska, Teresa / Steinhof-Radwańska, Katarzyna / Strzelczyk, Janusz / Sworczak, Krzysztof / Syrenicz, Anhelli / Szawłowski, Andrzej / Szczepkowski, Marek / Wachuła, Ewa / Zajęcki, Wojciech / Zemczak, Anna / Zgliczyński, Wojciech / Kos-Kudła, Beata. ·grazka3558@yahoo.pl. ·Endokrynol Pol · Pubmed #28540972.

ABSTRACT: This paper presents the updated Polish Neuroendocrine Tumour Network expert panel recommendations on the management of neuroendocrine neoplasms (NENs) of the stomach and duodenum, including gastrinoma. The recommendations discuss the epidemiology, pathogenesis, and clinical presentation of these tumours as well as their diagnosis, including biochemical, histopathological, and localisation diagnoses. The principles of treatment are discussed, including endoscopic, surgical, pharmacological, and radionuclide treatments. Finally, there are also recommendations on patient monitoring.

4 Review Cystic pancreatic neuroendocrine tumours - a gastroenterologist's point of view. 2018

Dąbkowski, Krzysztof / Kos-Kudła, Beata / Andrysiak-Mamos, Elżbieta / Syrenicz, Anhelli / Pilch-Kowalczyk, Joanna / Starzyńska, Teresa. ·Department of Gastroenterology, Pomeranian Medical University, Szczecin, Poland, Poland. dabkowskikrzysztof@wp.pl. ·Endokrynol Pol · Pubmed #29952422.

ABSTRACT: Cystic pancreatic tumors are detected with increasing frequency and remain a clinical problem. Since they have different potential of malignancy the management and decision making process is a hard task. Guidelines, concerning pancreatic cystic tumors indicate the management with mucinous, serous cystic pancreatic neoplasms and solid pseudopappilary tumor, while the management with pancreatic cystic neuroendocrine tumors is not included into these standards. This review tries to answer the question are the cystic pancreatic neuroendocrine tumors different entity from solid tumors of neuroendocrine origin.The management and differential diagnosis of these neoplasms with special focus on features on imaging studies allowing preoperative diagnosis are discussed.

5 Review Successful EUS-guided ethanol ablation of insulinoma, four-year follow-up. Case report and literature review. 2017

Dąbkowski, Krzysztof / Gajewska, Paula / Walter, Kamila / Londzin-Olesik, Magdalena / Białek, Andrzej / Andrysiak-Mammos, Elżbieta / Kos-Kudła, Beata / Starzyńska, Teresa. ·Department of Gastroenterology, Pomeranian Medical University, Szczecin, Poland, Poland. dabkowskikrzysztof@wp.pl. ·Endokrynol Pol · Pubmed #28819950.

ABSTRACT: INTRODUCTION: EUS-guided ethanol ablation of insulinoma is a new method of treatment of this neuroendocrine tumour. Ablation is recommended in patients who are poor surgical candidates or refuse surgery. We present a case of an 81-year-old female with symptomatic insulinoma, treated successfully with EUS-guided alcoholic ablation, along with a literature review including 28 other previously described cases. The effectiveness, safety of the therapy, and technical procedure-related issues are summarised. To the best of our knowledge, this is the first described case of successful insulinoma EUS-guided ablation in Poland. MATERIAL AND METHODS: We searched the PubMed/Medline database to identify cases of EUS-guided alcoholic ablation. Our analysis included 14 articles (case reports or case series), with a total of 27 patients and 31 tumours described, published before February 2017. RESULTS: The described tumours were relatively small (mean 13 mm), and the most common location was pancreatic head. The mean ethanol volume injected to the tumour was 1.8 ml and the concentration of infused alcohol varied from 95% to 98%.Side effects were observed in six cases; apart from one, they were mild and self-limiting. There was only one severe adverse event, treated conservatively with success. The median follow-up was 14.4 months (2-55 months). In all described cases ablation led to improvement of the symptoms and normalisation of glycaemia. CONCLUSIONS: The EUS-guided alcoholic ablation of insulinoma is a safe and effective method of treatment in patients who are poor surgical candidates and/or refuse surgery. The adverse effects are rare and mild and were observed when the volume of injected ethanol was equal to or above 3.0 ml. However, the data is limited, the follow-up is relatively short, and prospective studies are needed to confirm the long-term effects of treatment. The study shows also that there are important procedural differences (concentration and volume of alcohol, needle gauge, number of sessions) between the endoscopists, which should be specified.

6 Review [Pancreatic cancer microenvironment]. 2016

Dąbkowski, Krzysztof / Bogacka, Barbara / Tarnowski, Maciej / Starzyńska, Teresa. ·Pomeranian Medical University of Szczecin, Poland: Department of Gastroenterology. · Pomeranian Medical University of Szczecin, Poland: Department of Physiology. ·Pol Merkur Lekarski · Pubmed #28024135.

ABSTRACT: Pancreatic cancer remains one of the deadliest solid tumors in humans and an unsolved problem of today's medicine. Experimental studies reveal that the heterogeneous and complex pancreatic cancer microenvironment is responsible, not only for cancer growth, spread, development of metastases, but also for cancer recurrence and chemotherapy resistance. Chemotherapy affecting the cancer stroma is still under clinical and experimental research and remains hope for cure of pancreatic cancer. We present the cancer microenvironment characteristics and summary of experimental studies with use of agents affecting pancreatic cancer stroma.

7 Review Concise Review: Pancreatic Cancer and Bone Marrow-Derived Stem Cells. 2016

Błogowski, Wojciech / Bodnarczuk, Tomasz / Starzyńska, Teresa. ·Department of Internal Medicine, University of Zielona Góra, Zielona Góra, Poland drannab@wp.pl. · Division of Internal Medicine, 109th Military Hospital, Szczecin, Poland. · Department of Gastroenterology, Pomeranian Medical University in Szczecin, Szczecin, Poland. ·Stem Cells Transl Med · Pubmed #27217346.

ABSTRACT: SIGNIFICANCE: Different bone marrow-derived stem cell populations contribute to the development and/or progression of pancreatic cancer, and they might also be a promising "weapon" that can be used for anticancer treatments in humans. Even though the exact role of these stem cells in pancreatic cancer development and/or progression in humans still remains unclear, this concept continues to drive a completely novel scientific avenue in pancreatic cancer research and gives rise to innovative ideas regarding novel therapeutic modalities that can be safely offered to patients.

8 Review [Rare solid pancreatic tumors]. 2013

Dabkowski, Krzysztof / Kojder, Klaudyna / Smereczyński, Andrzej / Lubikowski, Jerzy / Patalan, Marek / Starzyńska, Teresa. ·Pomorski Uniwersytet Medyczny w Szczecinie, Katedra i Klinika Gastroenterologii. kgastro@sci.pam.szczecin.pl ·Pol Merkur Lekarski · Pubmed #24052992.

ABSTRACT: The most common tumor of the pancreas is cancer, which constitutes 85% of all pancreatic neoplasms. Cystic pancreatic tumors comprise 10% of malignancies. No more than 5% of pancreatic tumors are rare solid tumors as: neuroendocrine tumors, gastrointestinal stromal tumors, solid pseudopapillary tumors, pecomas, lymphomas, granulocytic sarcomas, schwannomas, lipomas, liposarcomas and metastases to pancreas. Nowadays, these tumors are diagnosed more commonly due to the developement and accessibility of the diagnostic imaging techniques. Moreover, the treatment and management of rare solid pancreatic tumors often differs from the management in pancreatic cancer what makes the differential diagnosis difficult and responsible challenge. The main purpose of this article is to present an actual data of epidemiology, clinical presentation, management and treatment of rare solid pancreatic tumors according to recent literature and self experience.

9 Article [Gastroenterological manifestations of von Hippel-Lindau disease - a case report]. 2017

Koniusz, Joanna / Dąbkowski, Krzysztof / Buczek, Katarzyna / Gomółka, Aleksandra / Starzyńska, Teresa. ·Department of Gastroenterology, Pomeranian Medical University, Szczecin, Poland; Department of General, Vascular and Transplantation Surgery, Marie Curie Hospital, Szczecin, Poland. · Department of Gastroenterology, Pomeranian Medical University, Szczecin, Poland. ·Pol Merkur Lekarski · Pubmed #28875972.

ABSTRACT: Gastrointestinal organs are involved in the course of von Hippel Lindau disease. Typically pancreas in von Hippel Lindau syndrome is a site of cystic and solid tumors. Differential diagnosis of pancreatic lesions includes benign lesions (cysts, serous cystic adenomas), potentially malignant (neuroendocrine) and malignant tumors(metastases).In this work we present a patient with VHL syndrome with pancreatic cysts and neuroendocrine tumor.

10 Article An Attempt to Evaluate Selected Aspects of "Bone-Fat Axis" Function in Healthy Individuals and Patients With Pancreatic Cancer. 2015

Blogowski, Wojciech / Dolegowska, Katarzyna / Deskur, Anna / Dolegowska, Barbara / Starzyńska, Teresa. ·From the Department of Internal Medicine, University of Zielona Góra, Zielona Góra, Poland (WB) · Department of Laboratory Diagnostics and Molecular Medicine, Pomeranian Medical University, Szczecin, Poland (KD) · Department of Gastroenterology, Pomeranian Medical University, Szczecin, Poland (AD) · Department of Microbiology and Immunological Diagnostics, Pomeranian Medical University in Szczecin, Szczecin, Poland (BD) · and Department of Gastroenterology and Internal Medicine, Warsaw Medical University, Warsaw, Poland (TS). ·Medicine (Baltimore) · Pubmed #26266370.

ABSTRACT: Recently, much attention has been paid to a potential biochemical cross-talk between the metabolism of the adipose tissue (AT) and bone (marrow), termed "bone-fat axis." We hypothesized that selected substances, participating in this "dialog," are associated with body mass and peripheral trafficking of bone marrow-derived stem cells (BMSCs) in both healthy individuals and patients with obesity-associated malignancies such as pancreatic adenocarcinoma.We performed an analysis of the systemic levels of selected substances involved in the regulation of bone (marrow) homeostasis (parathormone, calcitonin, osteopontin, osteonectin, stem cell factor [SCF], and fibroblast growth factor-23) in 35 generally healthy volunteers and 35 patients with pancreatic cancer. Results were correlated with the absolute number of circulating BMSCs and body mass values. Additionally, subcutaneous and visceral/omental AT levels of the aforementioned molecules were analyzed in lean and overweight/obese individuals.Intensified steady-state trafficking of only Lin-CD45 + CD133 + hematopoietic stem/progenitor cells was observed in overweight/obese individuals and this was associated with BMI values and elevated levels of both osteonectin and SCF, which also correlated with BMI. In comparison to healthy individuals, patients with cancer had significantly higher osteopontin levels and lower values of both osteonectin and osteonectin/osteopontin ratio. While no significant correlation was observed between BMI and the number of circulating BMSCs in patients with cancer, peripheral trafficking of CD34 + KDR + CD31 + CD45-endothelial progenitor cells and CD105 + STRO-1 + CD45-mesenchymal stem cells was associated with the osteonectin/osteopontin ratio, which also correlated with BMI (r = 0.52; P < 0.05). AT levels of the examined substances were similar to those measured in the plasma, except for osteonectin, which was about 10 times lower.Our study highlights the potential role of osteonectin, osteopontin, and SCF as communication signals between the bone (marrow) and AT in both healthy individuals and patients with pancreatic cancer. We postulate that these molecules may be overlooked biochemical players linking body mass and BMSCs with obesity-associated cancer development and/or progression in humans.

11 Article [Pancreatic solid pseudopapillary tumor--report of three cases]. 2014

Dabkowski, Krzysztof / Lubikowski, Jerzy / Głuszko, Rafał / Kowalski, Wojciech / Starzyńska, Teresa. · ·Pol Merkur Lekarski · Pubmed #24868901.

ABSTRACT: Three cases of young females with pancreatic solid pseudopapillary tumor (SPT) were reported. They were referred to Department of Gastroenterology, because of the ultrasonographical finding of the pancreatic tale tumor. In all presented cases, proper diagnosis was made preoperatively. The patients underwent surgical treatment, and remain symptoms-free with no features of recurrence of the disease (follow-up from 6 to 36 months).

12 Article Selected cytokines in patients with pancreatic cancer: a preliminary report. 2014

Błogowski, Wojciech / Deskur, Anna / Budkowska, Marta / Sałata, Daria / Madej-Michniewicz, Anna / Dąbkowski, Krzysztof / Dołęgowska, Barbara / Starzyńska, Teresa. ·Department of Public Health, University of Zielona Góra, Zielona Góra, Poland. · Department of Gastroenterology, Pomeranian Medical University in Szczecin, Szczecin, Poland. · Department of Medical Analytics, Pomeranian Medical University in Szczecin, Szczecin, Poland. ·PLoS One · Pubmed #24849506.

ABSTRACT: BACKGROUND/AIMS: Recent experimental studies have suggested that various cytokines may be important players in the development and progression of pancreatic cancer. However, these findings have not yet been verified in a clinical setting. METHODS: In this study, we examined the levels of a broad panel of cytokines, including interleukin (IL)-1, IL-6, IL-8, IL-10, IL-12, IL-17, and IL-23, as well as tumor necrosis factor alpha (TNFα) and granulocyte-colony stimulating factor (G-CSF) in patients with pancreatic adenocarcinoma (n=43), other pancreatic malignancies (neuroendocrine [n=10] and solid pseudopapillary tumors [n=3]), and healthy individuals (n=41). RESULTS: We found that there were higher levels of IL-6, IL-8, IL-10 and TNFα in patients with pancreatic cancer compared to healthy controls (for all, at least p<0.03). Cancer patients had lower IL-23 concentrations than healthy individuals and patients diagnosed with other types of malignancies (for both, p=0.002). Levels of IL-6, IL-8, IL-10, and IL-23 were significantly associated with the direct number of circulating bone marrow (BM)-derived mesenchymal or very small embryonic/epiblast-like stem cells (SCs) in patients with pancreatic cancer. Moreover, our study identified a potential ability of IL-6, IL-8, IL-10, IL-23, and TNFα levels to enable discrimination of pancreatic cancer from other pancreatic tumors and diseases, including acute and chronic pancreatitis and post-pancreatitis cysts (with sensitivity and specificity ranging between 70%-82%). CONCLUSIONS: Our study i) supports the significance of selected cytokines in the clinical presentation of pancreatic cancer, ii) highlights numerous associations between selected interleukins and intensified BMSCs trafficking in patients with pancreatic cancer, and iii) preliminarily characterizes the diagnostic potential of several cytokines as potential novel clinical markers of pancreatic cancer in humans.

13 Article An intensified systemic trafficking of bone marrow-derived stem/progenitor cells in patients with pancreatic cancer. 2013

Starzyńska, Teresa / Dąbkowski, Krzysztof / Błogowski, Wojciech / Zuba-Surma, Ewa / Budkowska, Marta / Sałata, Daria / Dołęgowska, Barbara / Marlicz, Wojciech / Lubikowski, Jerzy / Ratajczak, Mariusz Z. ·Department of Gastroenterology, Pomeranian Medical University, Szczecin, Poland. ·J Cell Mol Med · Pubmed #23672538.

ABSTRACT: Various experimental studies indicate potential involvement of bone marrow (BM)-derived stem cells (SCs) in malignancy development and progression. In this study, we comprehensively analysed systemic trafficking of various populations of BM-derived SCs (BMSCs), i.e., mesenchymal, haematopoietic, endothelial stem/progenitor cells (MSCs, HSCs, EPCs respectively), and of recently discovered population of very small embryonic/epiblast-like SCs (VSELs) in pancreatic cancer patients. Circulating CD133(+)/Lin(-)/CD45(-)/CD34(+) cells enriched for HSCs, CD105(+)/STRO-1(+)/CD45(-) cells enriched for MSCs, CD34(+)/KDR(+)/CD31(+)/CD45(-) cells enriched for EPCs and small CXCR4(+) CD34(+) CD133(+) subsets of Lin(-) CD45(-) cells that correspond to VSELs were enumerated and sorted from blood samples derived from 29 patients with pancreatic cancer, and 19 healthy controls. In addition, plasma levels of stromal-derived factor-1 (SDF-1), growth/inhibitory factors and sphingosine-1-phosphate (S1P; chemoattractants for SCs), as well as, of complement cascade (CC) molecules (C3a, C5a and C5b-9/membrane attack complex--MAC) were measured. Higher numbers of circulating VSELs and MSCs were detected in pancreatic cancer patients (P < 0.05 and 0.01 respectively). This trafficking of BMSCs was associated with significantly elevated C5a (P < 0.05) and C5b-9/MAC (P < 0.005) levels together with S1P concentrations detected in plasma of cancer patients, and seemed to be executed in a SDF-1 independent manner. In conclusion, we demonstrated that in patients with pancreatic cancer, intensified peripheral trafficking of selected populations of BMSCs occurs. This phenomenon seems to correlate with systemic activation of the CC, hepatocyte growth factor and S1P levels. In contrast to previous studies, we demonstrate herein that systemic SDF-1 levels do not seem to be linked with increased mobilization of stem cells in patients with pancreatic cancer.

14 Article [Helicobacter pylori infection in pancreatic cancer]. 2012

Gawin, Alicja / Wex, Thomas / Ławniczak, Małgorzata / Malfertheiner, Peter / Starzyńska, Teresa. ·Department of Gastroenterology, Pomeranian Medical University, Szczecin, Poland. k.gastro@sci.pam.szczecin.pl ·Pol Merkur Lekarski · Pubmed #22590913.

ABSTRACT: MATERIAL AND METHODS: 139 patients with pancreatic cancer and 177 controls were included in the study. Seropositivity for H. pylori, including CagA protein were assessed by the enzyme-linked immunosorbent assay and Western blot, respectively. The frequency of H. pylori in pancreatic cancer patients and controls were compared adjusted for age, sex, cigarette smoking and a family history of cancer in the logistic regresion model. RESULTS: No significant differences between pancreatic cancer patients and controls were seen according to H. pylori seropositivity (87.1 vs 82.5%; OR = 1.27; CI95%: 0.64-2.61; p = 0.514) and CagA seropositivity (83.5 vs 84.9%; OR = 0.90; CI95%: 0.46-1.73; p = 0.744). CONCLUSIONS: The study didn't support previous observations of H. pylori infection as a plausible pathogenic risk factor for pancreatic cancer development. The high prevalence of infection in the control group may explain why the earlier reports of a positive association between H. pylori infection and pancreatic cancer could not be confirmed in the study.

15 Article Is there any relationship between BRCA1 gene mutation and pancreatic cancer development? 2008

Lawniczak, Małgorzata / Gawin, Alicja / Białek, Andrzej / Lubiński, Jan / Starzyńska, Teresa. ·Department of Gastroenterology and Internal Diseases, Pomeranian Medical University, Szczecin, Poland. gosiaml7@wp.pl ·Pol Arch Med Wewn · Pubmed #19140568.

ABSTRACT: INTRODUCTION: Pancreatic cancer belongs to carcinomas associated with poor prognosis and low survival rate. It has been highlighted that the cancer risk is linked to both environmental and genetic factors. Available studies allow to estimate that genetic factors play a role in 5-10% of patients with pancreatic cancer. Beside other carcinomas, pancreatic cancer occurs in hereditary neoplastic syndromes associated with gene mutations, including CDKN2A, CHEK2, BRCA2. It has also been suggested that BRCA1 mutation is involved given the fact that BRCA1 mutation carriers are at increased risk for pancreatic cancer. However, a role of this mutation is not fully understood. OBJECTIVES: The purpose of the study was to assess the relationship between BRCA1 gene mutation and pancreatic cancer in Polish population. PATIENTS AND METHODS: 88 pancreatic cancer patients (56 males and 35 females) and 3784 carriers of BRCA1 mutation from 1637 families were enrolled in the study. Almost 65% of pancreatic cancer patients were cigarette smokers. Genotyping for constitutive BRCA1 gene mutation was performed in all patients with pancreatic cancer. ASA-PCR and PCR-RFLP methods were used to detect BRCA1 (5382insC, C61G, 4153delA) mutations. The frequency of pancreatic cancer in families of BRCA1 mutation carriers was evaluated. RESULTS: No carriers of BRCA1 mutation were identified in patients with pancreatic cancer. Only in 11 families (0.7%) with BRCA1 mutation carriers, pancreatic cancer was diagnosed. CONCLUSIONS: Our results suggest that there is no relationship between BRCA1 mutation and pancreatic cancer development in Polish population.

16 Article [Diagnostic and therapeutic guidelines for gastrointestinal neuroendocrine tumors (recommended by the Polish Network of Neuroendocrine Tumors)]. 2008

Kos-Kudła, Beata / Bolanowski, Marek / Handkiewicz-Junak, Daria / Jarzab, Barbara / Królicki, Leszek / Krzakowski, Maciej / Kunikowska, Jolanta / Nasierowska-Guttmejer, Anna / Nowak, Andrzej / Rydzewska, Grazyna / Starzyńska, Teresa / Szawłowski, Andrzej / Anonymous3300594. ·Klinika Endokrynologii, Katedra Patofizjologii i Endokrynologii, Slaski Uniwersytet Medyczny, Zabrze, Poland. endoklin@slam.katowice.pl ·Endokrynol Pol · Pubmed #18335400.

ABSTRACT: We have recently observed an increased interest in gastro-entero-pancreatic neuroendocrine tumors (GEP NET). They are rare cancer types and therefore collaborative effort of specialists in various disciplines of medicine is necessary to work out the diagnostic and therapeutic guidelines. In this publication we present general guidelines of the Polish Network of Neuroendocrine Tumors for the management of patients with GEP NET, developed at the Round Table Conference which took place in Kliczków near Wrocław in November 2007. In the subsequent parts of this publication, we present the rules of diagnostic and therapeutic management of: - endocrine tumors of the stomach and duodenum (including gastrinoma); - pancreatic endocrine tumors; - neuroendocrine tumors of the small intestine and the appendix; - neuroendocrine tumors of the colon. We hope that the proposed guidelines by Polish and foreign experts representing various disciplines of medicine, including endocrinology, gastroenterology, surgery, oncology, nuclear medicine and pathomorphology, will become a useful tool in the diagnostics and treatment of these patients.